Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate
Another one of the world's largest pharmaceutical companies is throwing its weight behind the development of a coronavirus vaccine. Novartis (NYSE: NVS) will partner with Massachusetts General Hospital to develop a SARS-CoV-2 vaccine candidate.
The Massachusetts Eye and Ear Institute, part of the nonprofit Mass General Brigham health system, has entered an agreement with AveXis, a gene-therapy developer that Novartis bought in 2018 for $8.7 billion, to mass-produce a vaccine candidate called AAVCOVID. It uses an adeno-associated viral (AAV) vector to deliver genetic blueprints that should spur the production of harmless protein fragments that resemble the spikes found on the surface of the coronavirus that causes COVID-19.
Image source: Getty Images.
Source Fool.com
